SCHEMBL6469221

SCHEMBL6469221

Nc1cnc(NCc2ccccc2)cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.57
ALDH1A1 P00352 1/20 0.57
HPGD P15428 1/20 0.57
KMT2A Q03164 1/20 0.57
HDAC3 O15379 2/20 0.53
NCOR1 O75376 2/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
FABP1 P07148 1/20 0.53
FABP6 P51161 1/20 0.53
EGFR P00533 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.49
POLB P06746 1/20 0.49
BACE1 P56817 1/20 0.47
TPH1 P17752 1/20 0.47
MAP4K4 O95819 1/20 0.47
NOS2 P35228 1/20 0.46
APP P05067 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5040443 0.83 L3MBTL1 (0.50) ALDH1A1HDAC3HDAC1HDAC2HDAC6
SCHEMBL22191398 0.79 ALDH1A1 (0.57) MEN1ALDH1A1HPGDKMT2AHDAC3
SCHEMBL7231916 0.79 FABP1 (0.58) MEN1ALDH1A1HPGDKMT2AHDAC3
SCHEMBL6469219 0.76 HDAC3 (0.64) MEN1ALDH1A1HPGDKMT2AHDAC3
SCHEMBL11060936 0.75 HTT (0.55) MEN1ALDH1A1KMT2AHDAC1EGFR
SCHEMBL6685508 0.75 EGFR (0.46) MEN1ALDH1A1HPGDKMT2AFABP1
SCHEMBL507498 0.74 FABP1 (0.56) MEN1ALDH1A1HPGDKMT2AHDAC1
SCHEMBL5134065 0.74 MEN1 (0.53) MEN1KMT2AEGFRPOLBBACE1
SCHEMBL10005387 0.74 CYP2D6 (0.56) MEN1ALDH1A1HPGDKMT2AFABP1
SCHEMBL13101047 0.74 FYN (0.59) MEN1ALDH1A1HPGDKMT2AFABP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US claimed
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders APP, BACE1, SNCA MEN1 978/4885ALDH1A1 2820/4885HPGD 3060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.